Evidence map›Paper›PMID 28191779›Full record

ArticleStem cells translational medicine2017

Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling.

Dan C Wilkinson, Jackelyn A Alva-Ornelas, Jennifer M S Sucre, Preethi Vijayaraj, Abdo Durra, Wade Richardson, Steven J Jonas, Manash K Paul, Saravanan Karumbayaram, Bruce Dunn and 1 more

Open access · goldAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 4 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Organoids: a systematic review of ethical issues.Stem cell research & therapy · 2022
    Pooled it
  3. Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Light-field tomographic fluorescence lifetime imaging microscopy.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. The evolution ofEuropean respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  19. Review
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Dan C WilkinsonDepartment of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California, USA.
Jackelyn A Alva-OrnelasDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Jennifer M S SucreDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Preethi VijayarajDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Abdo DurraDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Wade RichardsonDepartment of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California, USA.
Steven J JonasDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Manash K PaulDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
Saravanan KarumbayaramEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, California, USA.
Bruce DunnDepartment of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California, USA.
Brigitte N GompertsDavid Geffen School of Medicine at the University of California, Los Angeles, Department of Pediatrics, Children's Discovery and Innovation Institute, Los Angeles, California, USA.
University of California, Los Angeles · USMattel Children's Hospital · US

Funding

Development of a High-Throughput Screen for Pre-therapeutic Discovery in Idiopathic Pulmonary FibrosisR01GM114259 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAMOISEAUX, ROBERT, GOMPERTS, BRIGITTE N · 2015 to 2017
$1.1M
NIGMS NIH HHS R01 GM114259
6 · The paper itself

Abstract

Stem cell technologies, especially patient-specific, induced stem cell pluripotency and directed differentiation, hold great promise for changing the landscape of medical therapies. Proper exploitation of these methods may lead to personalized organ transplants, but to regenerate organs, it is necessary to develop methods for assembling differentiated cells into functional, organ-level tissues. The generation of three-dimensional human tissue models also holds potential for medical advances in disease modeling, as full organ functionality may not be necessary to recapitulate disease pathophysiology. This is specifically true of lung diseases where animal models often do not recapitulate human disease. Here, we present a method for the generation of self-assembled human lung tissue and its potential for disease modeling and drug discovery for lung diseases characterized by progressive and irreversible scarring such as idiopathic pulmonary fibrosis (IPF). Tissue formation occurs because of the overlapping processes of cellular adhesion to multiple alveolar sac templates, bioreactor rotation, and cellular contraction. Addition of transforming growth factor-β1 to single cell-type mesenchymal organoids resulted in morphologic scarring typical of that seen in IPF but not in two-dimensional IPF fibroblast cultures. Furthermore, this lung organoid may be modified to contain multiple lung cell types assembled into the correct anatomical location, thereby allowing cell-cell contact and recapitulating the lung microenvironment. Our bottom-up approach for synthesizing patient-specific lung tissue in a scalable system allows for the development of relevant human lung disease models with the potential for high throughput drug screening to identify targeted therapies. Stem Cells Translational Medicine 2017;6:622-633.

Indexed as

Cell Culture TechniquesBioreactorsCell DifferentiationCell LineageCells, CulturedFibroblastsHumansIdiopathic Pulmonary FibrosisInduced Pluripotent Stem CellsLungOrganoidsPhenotypeTime FactorsTissue EngineeringTransforming Growth Factor beta1Transforming Growth Factor beta1Disease modelingLungThree-dimensional cell cultureTissue engineering

Identifiers

PMID28191779
PMCPMC5442826
OpenAlexW2520176498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.